Bladder cancer ranks among the ten most common types of cancer worldwide. The main treatment is bladder removal surgery, and ...

The bladder cancer treatment landscape is rapidly evolving, particularly for patients who don’t respond to bacillus ...

The trial showed that 63% of patients achieved a complete response (CR) at any time after receiving detalimogene coraplasmid.

Imagine a targeted approach to bladder cancer that spares healthy cells while delivering chemotherapy directly to cancerous ...

Mitchell, who has served as a councilman for 23 years, was diagnosed with bladder cancer in February after previously being ...

The experts agreed that perioperative approaches in muscle-invasive bladder cancer continue to evolve. Ongoing data will ...

Gene's Phase 2 LEGEND trial shows 63% response in BCG-unresponsive bladder cancer, supporting plans for a 2026 FDA filing.

The latest update is out from Theralase Technologies ( (TSE:TLT) ).

The company announced that detalimogene demonstrated a 62% complete response rate at 6 months in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.

Shares of Engene Holdings Inc. (NASDAQ:ENGN) were trading at $10.34, up $4.33, or 72%, on word of additional preliminary data from the pivotal cohort of its ongoing phase II Legend trial testing ...

Data from the Colorado Central Cancer Registry shows Routt County had the highest rate of prostate cancer among all Colorado ...

Phase 2 data presented at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting show deep and durable tumor regressions in heavily pre-treated melanoma patients, with a mild safety ...